Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21516821 | 0.79 | KMT2A (0.44) | KMT2AMEN1MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL14500083 | 0.75 | KMT2A (0.45) | AGBL2KMT2AMEN1MAPK1RAB9A | |
| SCHEMBL20288206 | 0.71 | — | — | |
| SCHEMBL16689550 | 0.70 | KMT2A (0.44) | AGBL2KMT2AMEN1MAPK1RAB9A | |
| SCHEMBL23025588 | 0.69 | RXRA (0.30) | — | |
| SCHEMBL12303237 | 0.64 | KMT2A (0.44) | AGBL2KMT2AMEN1MAPK1RAB9A | |
| SCHEMBL9967732 | 0.63 | KMT2A (0.61) | KMT2AMEN1MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL21161219 | 0.62 | KMT2A (0.36) | KMT2AMEN1MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL26199789 | 0.62 | AGBL2 (0.57) | AGBL2KMT2AMEN1MAPK1SMN1; SMN2 | |
| SCHEMBL15481059 | 0.61 | PSMD14 (0.33) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | AGBL2 1515/4885KMT2A 3777/4885MEN1 3259/4885 |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | AGBL2 1515/4885KMT2A 3777/4885MEN1 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.